Form 6-K Immatics N.V. For: Dec 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mizuho on Immatics (IMTX): 'BMS Cell Therapy Collaboration Discontinued, but No Material Impact; Stock Attractive Here'
December 16, 2024 5:47 AM ESTMizuho analyst Graig Suvannavejh reiterated an Outperform rating and $16.00 price target on Immatics (NASDAQ: IMTX)
The analyst comments "IMTX disclosed the termination by partner Bristol Myers Squibb/BMS (BMY, not rated) of a collaboration regarding the development of novel TCR-based,... More
